Filing Details
- Accession Number:
- 0001144204-15-053486
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-09-02 17:55:40
- Reporting Period:
- 2015-09-01
- Filing Date:
- 2015-09-02
- Accepted Time:
- 2015-09-02 17:55:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 810509 | Navidea Biopharmaceuticals Inc. | NAVB | In Vitro & In Vivo Diagnostic Substances (2835) | 311080091 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1195766 | L Brent Larson | 5600 Blazer Parkway, Suite 200 Dublin OH US 43017 | Evp, Cfo, Treas And Sec'y | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2015-09-01 | 12,500 | $1.88 | 259,737 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Sales effected pursuant to a 10b5-1 trading plan adopted by Mr. Larson on March 13, 2015.
- Weighted average of sales prices ranging from $1.83 to $1.91 per share. Mr. Larson undertakes to provide upon request by the Staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, fullinformation regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
